Company Overview and News

4
Here's Why You Should Invest in Boston Scientific Stock Now

2018-10-09 zacks
Boston Scientific Corporation (BSX - Free Report) has been gaining investor confidence on consistently encouraging results. Over the past six months, the company’s share price has outperformed its industry. The stock has gained 27.1% compared with the industry’s 19% rally. Also, the company has outperformed the S&P 500’s 8.7% rise.
MASI BSX AMED ISRG

10
How Indian stent maker SMT is taking the battle to MNC shores

2018-10-09 moneycontrol
Sahajanand Medical Technologies, or SMT, the Surat-based maker of cardiac stents isn’t content with what it has achieved in India. The management now wants to take the battle to foreign shores.
ABT YESBANK 532648 YYBKY ABT BSX MS

7
Why Boston Scientific (BSX) is Poised to Beat Earnings Estimates Again

2018-10-05 zacks
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Boston Scientific (BSX - Free Report) , which belongs to the Zacks Medical - Products industry, could be a great candidate to consider.
BSX YY

3
Can You Still Profit From Boston Scientific’s Tremendous Run?

2018-10-03 investorplace
Over the last six months, Boston Scientific (NYSE:BSX) has experienced an incredible rally. BSX stock has moved higher in 24 of the past 28 weeks, a streak that started back in March.
BSX

4
Boston Scientific Grows on Acquisitions, Product Launches

2018-10-03 zacks
On Oct 1, we issued an updated research report on Boston Scientific Corporation (BSX - Free Report) . The company’s recent acquisitions have added various new products (though many are under development) with immense potential to its portfolio. The stock carries a Zacks Rank #2 (Buy).
MASI BSX AMED ISRG

5
Baxter (BAX) Collaborates With USC CBC to Digitize Healthcare

2018-10-02 zacks
Baxter International Inc. (BAX - Free Report) recently announced collaboration with the University of Southern California Center for Body Computing (“USC CBC”) to develop innovative digital solutions designed to help save and sustain lives. With the development, Baxter aims to integrate digital capabilities to advance care.
BSX SYK NR BAX MDT

85
Top Analyst Upgrades and Downgrades: Boston Scientific, Etsy, General Electric, Morgan Stanley, SeaWorld, Skechers, Shopify, Square, Tesla and More

2018-10-02 247wallst - 2
Stocks were taking a breather on Tuesday, but that is after the Canada trade deal sent the Dow Jones industrials up about 190 points and the S&P 500 up over 10 points. While the U.S. indexes are effectively at all-time highs, many investors have seen lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how to position their investments for the rest of 2018 and into 2019.
GE SQ GEC SQNXF SKX SEAS BSX TSLA TRI GNE MS ECL ETSY

12
7 Stocks to Buy Thanks to Trump’s New Trade Deal

2018-10-02 investorplace
U.S. equities are moving powerfully higher on Monday, with the major large-cap indices testing recent record highs, after the United States reached a new trade deal with Mexico and Canada. Effectively “NAFTA 2.0”, the deal, which carries the moniker USMCA, will solve deficiencies in the original NAFTA deal and open new markets for U.S. farmers and manufacturers … at least according to President Trump.
UAL HON BSX CAT CSCO MSFT BA DHR

25
3 Big Stock Charts for Thursday: Western Union, Boston Scientific and Zions Bancorp

2018-09-27 investorplace
On Wednesday the bulls were largely in charge leading up to and even after the Federal Reserve ratcheted up interest rates by the expected quarter of a point. With a little time to think about it though, before the closing bell rang, doubt dragged the S&P 500 to a loss of 0.33%. The Nasdaq followed suit, closing down 0.21%.
GPRO ZION WU NDAQ BSX AMD

5
Boston Scientific Thrives in Urology on New LithoVue Empower

2018-09-25 zacks
Boston Scientific Corporation (BSX - Free Report) recently launched its new urology device globally. Called LithoVue Empower Retrieval Deployment Device, it will be used together with the LithoVue Single-Use Digital Flexible Ureteroscope and a compatible nitinol retrieval basket. This latest development remains in line with Boston Scientific’s strategy to address inefficiencies during stone procedures.
MASI BSX VEEV ATHN

4
Boston Scientific's FDA Nod for Eluvia Stent Expands PI Suite

2018-09-25 zacks
Boston Scientific Corporation’s (BSX - Free Report) recent receipt of Premarket Approval (PMA) to market the Eluvia Drug-Eluting Vascular Stent System expanded its Peripheral Interventions (PI) suite. Notably, the company received CE Mark for the stent system in 2016.
MASI BSX AMED ISRG

10
Abbott: MitraClip Success Provides Upside For Stock

2018-09-24 seekingalpha
Expectations were low for the COAPT trial due to disappointing results from French-funded study MITRA-FR. However, some analysts still believed COAPT was different enough to see a more positive outcome.
ABT BSX ABT EW

3
Boston Scientific's drug-coated stent gets FDA approval

2018-09-24 channelnewsasia
REUTERS: The U.S. Food and Drug Administration on Monday approved Boston Scientific Corp's drug-coated stent Eluvia to treat narrowed arteries in the leg.
BSX

3
Boston Scientific's drug-coated stent gets FDA approval

2018-09-24 reuters
(Reuters) - The U.S. Food and Drug Administration on Monday approved Boston Scientific Corp’s drug-coated stent Eluvia to treat narrowed arteries in the leg.
BSX

20
3 MedTech Stocks for Safe Returns as Hurricane Fears Peak

2018-09-21 zacks
An upbeat economic scenario and strong growth in corporate earnings have encouraged investors to load up on U.S. stocks. The Dow Jones Industrial Average’s rise to an all-time high reflects the bullishness.
MASI QDEL BSX WBA ISRG UTX CVS MDT EOG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to BSX / Boston Scientific Corp. on message board site Silicon Investor.

belo sun bsx on the tsxv: belo sun bsx on the tsxv: belo sun bsx on the tsxv: Boston Scientific (BSX) Any Comments??? Boston Scientific (BSX) Any Comments??? Boston Scientific (BSX) Any Comments???
Boston Scientific Boston Scientific Boston Scientific Borealis Tech (BSXC) CANOTC is either... Borealis Tech (BSXC) CANOTC is either... Borealis Tech (BSXC) CANOTC is either...
IBS Interactive, Inc. (IBSX) IBS Interactive, Inc. (IBSX) IBS Interactive, Inc. (IBSX) Black Sea Energy (BSX) Black Sea Energy (BSX) Black Sea Energy (BSX)
CUSIP: 101137107